Jaguar Health Compliant with Nasdaq Bid Price Rule
Jaguar Health received formal notice from Nasdaq that it has regained compliance with Listing Rule 5550(a)(2), the Bid Price Rule, removing the threat of delisting. CEO Lisa Conte highlighted that Q1 2026 net revenue surged 816% year-over-year and 527% quarter-over-quarter, driven by a US out-license agreement with Future Pak for Mytesi and Canalevia-CA1.
Key figures
- Revenue
- 0
- Revenue Yoy
- 816%
- Q1 revenue qoq growth
- 527%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.